Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Literature
1.
Berlin NI. Prologue: polycythemia Vera. The closing of the Wasserman-polycythemia Vera study group era. Semin Hematol. 1997;34(1):1–5.PubMed
2.
Stein BL, ST O, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, et al. Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(33):3953–60.CrossRef
3.
Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372–5.PubMed
4.
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–21.CrossRefPubMed
5.
Barraco D, Cerquozzi S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017;7(3):e538.CrossRefPubMedPubMedCentral
6.
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81.CrossRefPubMedPubMedCentral
7.
Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances. 2016;1(1):21–30.CrossRef
8.
Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821–9.CrossRefPubMedPubMedCentral
9.
Foucar CE, Stein BL. Contemporary use of interferon therapy in the myeloproliferative neoplasms. Curr Hematol Malig Rep. 2017.
10.
Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, et al. Symptomatic profiles of patients with polycythemia Vera: implications of inadequately controlled disease. J Clin Oncol: Off J Am Soc Clin Oncol. 2016;34(2):151–9.CrossRef
11.
Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey. Cancer. 2017;123(3):449–58.CrossRefPubMed
Metadata
Title
Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?
Authors
Brady L Stein
Srdan Verstovsek
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 6/2017
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0423-9

Other articles of this Issue 6/2017

Current Hematologic Malignancy Reports 6/2017 Go to the issue

CART and Immunotherapy (M Ruella, Section Editor)

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer

Acute Myeloid Leukemias (H Erba, Section Editor)

Methods of Detection of Measurable Residual Disease in AML

Myelodysplastic Syndromes (M Savona, Section Editor)

Models of Prognostication in Chronic Myelomonocytic Leukemia

Invited Commentary

Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

Acute Myeloid Leukemias (H Erba, Section Editor)

Measurement of Residual Disease in Acute Myeloid Leukemia

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits